Highly sensitive immunoassay of free prostate-specific antigen in serum using europium(III) nanoparticle label technology

被引:74
作者
Soukka, T [1 ]
Antonen, K [1 ]
Härmä, H [1 ]
Pelkkikangas, AM [1 ]
Huhtinen, P [1 ]
Lövgren, T [1 ]
机构
[1] Univ Turku, Dept Biotechnol, FIN-20520 Turku, Finland
关键词
prostate-specific antigen; nanoparticle label technology; time-resolved fluorometry;
D O I
10.1016/S0009-8981(02)00376-5
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Recent proceedings in utilization of europium(III) chelate-dyed polystyrene nanoparticles as labels have combined the advantages of an enhanced monovalent binding affinity and a high specific activity of nanoparticle-antibody bioconjugate. Our objective was to evaluate the performance of the nanoparticle label technology with biological samples in an immunoassay of free prostate-specific antigen (PSA-F) using a standard microtitration well platform. Methods: Long-lifetime luminescent europium(III)-chelate nanoparticles, 107 nm in diameter, were coated with a PSA-F specific monoclonal antibody. The two-step noncompetitive immunoassay was performed in a microtitration well coated with a second monoclonal antibody. The signal of the surface-bound nanoparticle-antibody bioconjugates was measured directly from the bottom of the well using a standard time-resolved plate fluorometer. Results: The detection limit (mean + 2SD) of the nanoparticle-based PSA-F assay was 0.21 ng/l using a 20-mul sample volume. The assay response was linear up to 5 mug/l, and the functional sensitivity was approximately 0.5 ng/l. The within-run imprecision for spiked serum samples at concentrations 0.0005-0.5 mug/l was 6.4-21.8%, and the within-run and between-run imprecisions for serum samples at concentrations 0.2-2.5 mug/l were 3.4-7.2% and 4.4-7.6%, respectively. The concentrations obtained from serum samples correlated well with the reference immunoassay; slope = 1.018 +/- 0.018; intercept = 0.012 +/- 0.021 mug/l; S-y/x = 0.112 mug/l; r = 0.993; n = 51. Conclusions: The developed method demonstrated acceptable performance characteristics allowing clinical studies utilizing patient samples with extremely low concentrations of PSA-F. The present assay detected PSA-F in most of samples from prostatectomized men and in few samples from healthy women that were nondetectable according to the reference immunoassay. (C) 2002 Elsevier Science B.V All rights reserved.
引用
收藏
页码:45 / 58
页数:14
相关论文
共 40 条
  • [1] Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater
    Becker, C
    Piironen, T
    Pettersson, K
    Hugosson, J
    Lilja, H
    [J]. UROLOGY, 2000, 55 (05) : 694 - 699
  • [2] Becker C, 2000, CLIN CHEM, V46, P198
  • [3] Black MH, 2000, CLIN CANCER RES, V6, P467
  • [4] Diamandis EP, 1996, CLIN CHEM, V42, P853
  • [5] DICKSON EFG, 1995, J PHOTOCH PHOTOBIO B, V27, P3
  • [6] EKINS RP, 1991, CLIN CHEM, V37, P1955
  • [7] EKINS RP, 1985, PURE APPL CHEM, V57, P437
  • [8] ENZYME-AMPLIFIED LANTHANIDE LUMINESCENCE FOR ENZYME DETECTION IN BIOANALYTICAL ASSAYS
    EVANGELISTA, RA
    POLLAK, A
    TEMPLETON, EFG
    [J]. ANALYTICAL BIOCHEMISTRY, 1991, 197 (01) : 213 - 224
  • [9] Ferguson RA, 1996, CLIN CHEM, V42, P675
  • [10] Use of the complex between prostate specific antigen and α1-protease inhibitor for screening prostate cancer
    Finne, P
    Zhang, WM
    Auvinen, A
    Leinonen, J
    Määttänen, L
    Rannikko, S
    Tammela, TLJ
    Stenman, UH
    [J]. JOURNAL OF UROLOGY, 2000, 164 (06) : 1956 - 1960